|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1997-9-4
|
|
pubmed:abstractText |
A 61-year-old man with pulmonary and bone metastases from a primary transitional cell carcinoma of the prostate (TCCP) refractory to MVAC was treated with mitoxantrone 16 mg/m2 i.v. at 3-week intervals. With this, he experienced an objective partial remission lasting 5 months and a significant decrease in cancer-related symptoms. Mitoxantrone deserves further evaluation in this rare disease.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Mitoxantrone,
http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0277-3732
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
381-2
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:9256894-Antibiotics, Antineoplastic,
pubmed-meshheading:9256894-Antimetabolites, Antineoplastic,
pubmed-meshheading:9256894-Antineoplastic Agents,
pubmed-meshheading:9256894-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:9256894-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9256894-Bone Neoplasms,
pubmed-meshheading:9256894-Carcinoma, Transitional Cell,
pubmed-meshheading:9256894-Cisplatin,
pubmed-meshheading:9256894-Disease Progression,
pubmed-meshheading:9256894-Doxorubicin,
pubmed-meshheading:9256894-Fatal Outcome,
pubmed-meshheading:9256894-Follow-Up Studies,
pubmed-meshheading:9256894-Humans,
pubmed-meshheading:9256894-Injections, Intravenous,
pubmed-meshheading:9256894-Lung Neoplasms,
pubmed-meshheading:9256894-Male,
pubmed-meshheading:9256894-Methotrexate,
pubmed-meshheading:9256894-Middle Aged,
pubmed-meshheading:9256894-Mitoxantrone,
pubmed-meshheading:9256894-Prostatic Neoplasms,
pubmed-meshheading:9256894-Remission Induction,
pubmed-meshheading:9256894-Vinblastine
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Mitoxantrone in the treatment of metastatic transitional cell carcinoma of the prostate. A case report.
|
|
pubmed:affiliation |
Ontario Cancer Treatment and Research Foundation, Canada.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
